Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials.
心衰竭患者中 Semaglutide 與安慰劑的比較:SELECT、FLOW、STEP-HFpEF 和 STEP-HFpEF DM 隨機試驗的綜合分析。
Lancet 2024-09-02
Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials.
Semaglutide與安慰劑在肥胖相關心臟衰竭患者中的比較:STEP-HFpEF和STEP-HFpEF DM隨機試驗的綜合分析。
Lancet 2024-04-10
Semaglutide and Diuretic Use in Obesity-Related Heart Failure with Preserved Ejection Fraction: A Pooled Analysis of the STEP-HFpEF and STEP-HFpEF-DM trials.
Semaglutide與利尿劑在與肥胖相關的保留射血分數心臟衰竭中的應用:STEP-HFpEF和STEP-HFpEF-DM試驗的綜合分析。
Eur Heart J 2024-05-13
Efficacy and safety of semaglutide in patients with heart failure with preserved ejection fraction and obesity.
Semaglutide在心臟收縮功能保留但合併肥胖症患者中的療效和安全性。
Clin Cardiol 2024-05-22
Semaglutide in Heart Failure: A Systematic Review of Outcomes of Semaglutide in Heart Failure Patients.
心衰竭中的 Semaglutide:心衰竭患者中 Semaglutide 結果的系統性回顧。
Cureus 2024-08-16
Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial.
Semaglutide 與肥胖及心臟衰竭患者的心血管結果:SELECT 試驗的預先指定分析。
Lancet 2024-08-24
Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial.
FLOW 試驗中 Semaglutide 對糖尿病和慢性腎病心衰竭結果的影響。
J Am Coll Cardiol 2024-09-01
Effect of Semaglutide on Cardiac Structure and Function in Patients With Obesity-Related Heart Failure.
Semaglutide 對於肥胖相關心臟衰竭患者心臟結構和功能的影響。
J Am Coll Cardiol 2024-09-01